Lloyd George W., an insider at Royalty Pharma PLC (RPRX), sold 230 shares of the company's stock on November 18, 2025, at a price of $38.29 per share. The total transaction value amounted to approximately $9,000. Following this sale, George retains 230 shares in the company.
Royalty Pharma, headquartered in New York City, engages in providing drug development services and collaborates with a range of innovators in the biopharmaceutical industry. The firm boasts a market capitalisation of $22.0 billion, a P/E ratio of 28.81, and an EPS of 1.33. The company is scheduled to report its next earnings on August 4, 2026, with an estimated EPS of $1.34 and revenue of $709.5 million.
Insider transactions such as this one are reported to the SEC, offering transparency regarding executives' views on their company's stock. While such selling activity can reflect various personal financial decisions, it should be viewed in the context of broader insider trading patterns rather than in isolation. Investors are encouraged to consider multiple transactions over time to better assess insider sentiment.